News & Updates

For patients undergoing concurrent chemoradiotherapy (CCRT), treatment with either weekly or every-3-weeks fosaprepitant helps reduce nausea and vomiting caused by CCRT, with no difference in the effect, as reported in a study.

Treatment with the immune checkpoint inhibitor avelumab in the second-line setting confers survival and disease control benefits in patients with deficient mismatch repair and/or microsatellite instability (dMMR/MSI) metastatic colorectal cancer (mCRC) when compared with standard treatment, with a favourable safety profile, according to the results of the phase II SAMCO-PRODIGE 54 trial.

An expert-led public forum highlighted colorectal health awareness and early screening of people aged 45 and above, as key steps to reduce the burden of colorectal cancer (CRC) in Malaysia.

In patients with primary biliary cholangitis (PBC), changes in the GLOBE score (ΔGLOBE) brought about by treatment with ursodeoxycholic acid (UDCA) are predictive of liver transplantation (LT)-free survival, reports a study.

In the first-line treatment of Helicobacter pylori (H pylori) infection, 14-day hybrid therapy and 10-day bismuth quadruple therapy demonstrate superiority over 14-day high-dose dual therapy, reports a Taiwan study. However, high-dose therapy results in fewer adverse events than hybrid bismuth quadruple therapies.

Treatment with vedolizumab is associated with a reduced adjusted risk of severe Clostridioides difficile infection (CDI), but not total CDI, in patients with ulcerative colitis (UC), reports a study. Additionally, cytomegalovirus colitis (CMVC) is not seen in those who initiated vedolizumab.